Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors

BMC Infectious Diseases

Maarten W Taal²  Christopher W McIntyre²  Wiam A Alashek¹ 

[1] School of Graduate Entry Medicine, University of Nottingham, Nottingham, UK;Department of Renal Medicine, Derby Hospitals NHS Foundation Trust, Derby, UK

关键词: Prevalence;    Nosocomial infection;    Libya;    Incidence;    Hepatitis C;    Hepatitis B;    Haemodialysis;   

Others  :  1159626
DOI  :  10.1186/1471-2334-12-265

 received in 2012-01-25, accepted in 2012-10-16,  发布年份 2012

【 摘 要 】

Background

Patients receiving maintenance haemodialysis (HD) are at higher risk for acquiring Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections than the general population. Strict infection control measures are essential to prevent nosocomial transmission. We aimed to investigate the incidence and prevalence of HBV and HCV infection in the HD population of Libya as well as risk factors for infection.

Methods

All adult patients receiving maintenance HD (n=2382) in Libyan dialysis centres (n=39) were studied between May 2009 and October 2010. Testing for Hepatitis B surface antigen (HBsAg) and anti-HCV antibodies was performed at initiation of dialysis and every 3–6 months thereafter. Patients who were sero-negative for HBV and HCV (n=1160) were followed up for 1 year to detect sero-conversions.

Results

Participant median age was 49 years and 58% were male. 831 patients (34.9%) were sero-positive for HBV and/or HCV (anti-HCV positive 31.1%; HBsAg positive 2.6%; both positive 1.2%). Of the sero-positive patients 4.7% were known to be infected before the initiation of HD. The prevalence of HBV±HCV infection varied widely between HD centres from 0% to 75.9%. Sero-positive patients were younger, had longer time on dialysis and more previous blood transfusions. Prospective follow-up revealed an incidence of sero-conversion of 7.7% during 1 year (7.1% HCV; 0.6% HBV). Wide variation in rates of newly acquired infections was observed between dialysis centres. All new HBV cases were referred from centres already treating HBV infected patients. New HCV infections were reported in most centres but the rate of HCV sero-conversion varied widely from 1.5% to 31%. Duration of dialysis, history of previous renal transplant and history of receiving HD in another centre in Libya were significantly associated with sero-conversion.

Conclusion

Patients on maintenance HD in Libya have a high incidence and prevalence of HCV infection and lower rates of HBV infection. The factors associated with HBV and HCV infection are highly suggestive of nosocomial transmission within HD units. Urgent action is required to improve infection control measures in HD centres and to reduce dependence on blood transfusions for the treatment of anaemia.

【 授权许可】

   
2012 Alashek et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Fabrizi F, Poordad FF, Martin P: Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002, 36(1):3-10.
• [2]Fabrizi F, Lunghi G, Martin P: Hepatitis B virus infection in hemodialysis: recent discoveries. J Nephrol 2002, 15(5):463-468.
• [3]Taal MW, van Zyl-Smit R: Hepatitis C virus infection in chronic haemodialysis patients–relationship to blood transfusions and dialyser re-use. S Afr Med J 2000, 90(6):621-625.
• [4]Knudsen F, Wantzin P, Rasmussen K, Ladefoged SD, Lokkegaard N, Rasmussen LS, Lassen A, Krogsgaard K: Hepatitis C in dialysis patients: relationship to blood transfusions, dialysis and liver disease. Kidney Int 1993, 43(6):1353-1356.
• [5]Allander T, Medin C, Jacobson SH, Grillner L, Persson MA: Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol 1994, 43(4):415-419.
• [6]Le Pogam S, Le Chapois D, Christen R, Dubois F, Barin F, Goudeau A: Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. J Clin Microbiol 1998, 36(10):3040-3043.
• [7]Ozer A, Yakupogullari Y, Beytur A, Beytur L, Koroglu M, Salman F, Aydogan F: Risk factors of hepatitis B virus infection in turkey: a population-based, case–control study: risk factors for HBV infection. Hepat Mon 2011, 11(4):263-268.
• [8]Fabrizi F, Marzano A, Messa P, Martin P, Lampertico P: Hepatitis B virus infection in the dialysis population: current perspectives. Int J Artif Organs 2008, 31(5):386-394.
• [9]Taal MW, van Zyl-Smit R: Cost-effectiveness of hepatitis B vaccination in haemodialysis patients. S Afr Med J 2001, 91(4):340-344.
• [10]Mohamed WZ: Prevention of hepatitis C virus in hemodialysis patients: five years experience from a single center. Saudi J Kidney Dis Transpl 2010, 21(3):548-554.
• [11]Patel PR, Thompson ND, Kallen AJ, Arduino MJ: Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis 2010, 56(2):371-378.
• [12]Saune K, Kamar N, Miedouge M, Weclawiak H, Dubois M, Izopet J, Rostaing L: Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant 2010, 26(7):2309-2316.
• [13]Alashek WA, McIntyre CW, Taal MW: Provision and quality of dialysis services in Libya. Hemodial Int 2011, 15(4):444-452.
• [14]Elzouki A, Esmeo M, Samod M, Abonaja A, Alagi B, Daw M: Prevalence of hepatitis B, C and HIV infection in Libya: a population-based nationwide seropepidemiological study. Liver Int 2006, 26:20.
• [15]Elzouki AN: Hepatitis B infection in Libya:The magnitude of the problem. The Libyan Journal of Infectious Diseases 2008, 2(1):20-25.
• [16]Daw MA, Elkaber MA, Drah AM, Werfalli MM, Mihat AA, Siala IM: Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. Saudi Med J 2002, 23(11):1356-1360.
• [17]Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, et al.: The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355(9207):887-891.
• [18]Lavanchy D: The global burden of hepatitis C. Liver Int 2009, 29(Suppl 1):74-81.
• [19]Te HS, Jensen DM: Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010, 14(1):1-21. vii
• [20]WHO: Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the viral hepatitis prevention board, antwerp, belgium. J Viral Hepat 1999, 6(1):35-47.
• [21]Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE: Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002, 51(3):429-433.
• [22]Boulaajaj K, Elomari Y, Elmaliki B, Madkouri B, Zaid D, Benchemsi N: Prevalence of hepatitis C, hepatitis B and HIV infection among haemodialysis patients in Ibn-rochd university hospital, casablanca. Nephrol Ther 2005, 1(5):274-284.
• [23]Souqiyyeh MZ, Al-Attar MB, Zakaria H, Shaheen FA: Dialysis centers in the kingdom of saudi arabia. Saudi J Kidney Dis Transpl 2001, 12(3):293-304.
• [24]Jemni S, Ikbel K, Kortas M, Mahjoub J, Ghachem L, Bidet JM, Boukef K: Seropositivity to hepatitis C virus in Tunisian haemodialysis patients. Nouv Rev Fr Hematol 1994, 36(5):349-351.
• [25]Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, Keles H: Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 2006, 28(8):729-735.
• [26]Batieha A, Abdallah S, Maghaireh M, Awad Z, Al-Akash N, Batieneh A, Ajlouni KA: Epidemiology and cost of haemodialysis in Jordan. East Mediterr Health J 2007, 13(3):654-663.
• [27]Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin NW: Mortality among hemodialysis patients in europe, japan, and the united states: case-mix effects. Am J Kidney Dis 2004, 44(5 Suppl 2):16-21.
• [28]Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, Saito A, LaBrecque J, Port FK, Young EW: Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003, 63(6):2222-2229.
• [29]Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA, Yoshida CF, Martins RM: Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz 2006, 101(6):689-692.
• [30]Chandra M, Khaja MN, Hussain MM, Poduri CD, Farees N, Habeeb MA, Krishnan S, Ramareddy GV, Habibullah CM: Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure. Intervirology 2004, 47(6):374-376.
• [31]Qadi AA, Tamim H, Ameen G, Bu-Ali A, Al-Arrayed S, Fawaz NA, Almawi WY: Hepatitis B and hepatitis C virus prevalence among dialysis patients in Bahrain and Saudi Arabia: a survey by serologic and molecular methods. Am J Infect Control 2004, 32(8):493-495.
• [32]Telaku S, Fejza H, Elezi Y, Bicaj T: Hepatitis B and C in dialysis units in Kosova. Virol J 2009, 6:72. BioMed Central Full Text
• [33]SCOT: Saudi centre for organ transplantation- annual report 2009. 2009. ( https://www.scot.org.sa/en/M webcite) accessed July 2010
• [34]Al Hijazat M, Ajlouni YM: Hepatitis B infection among patients receiving chronic hemodialysis at the royal medical services in jordan. Saudi J Kidney Dis Transpl 2008, 19(2):260-267.
• [35]Alashek WA, McIntyre CW, Taal MW: Determinants of survival in patients receiving dialysis in Libya. Hemodial Int 2012. [Epub ahead of print]
• [36]Saxena AK, Panhotra BR: The vulnerability of middle-aged and elderly patients to hepatitis C virus infection in a high-prevalence hospital-based hemodialysis setting. J Am Geriatr Soc 2004, 52(2):242-246.
• [37]Mostaghni AA, Soltanian A, Mokhtari E, Japoni S, Mehrabani D: Seroprevalence of hepatitis B virus among hemodialysis patients in Bushehr province, southern Iran: HBV seroprevalence in hemodialysis patients. Hepat Mon 2011, 11(3):200-202.
• [38]Hardy NM, Sandroni S, Danielson S, Wilson WJ: Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol 1992, 38(1):44-48.
• [39]Jasuja S, Gupta AK, Choudhry R, Kher V, Aggarwal DK, Mishra A, Agarwal M, Sarin A, Mishra MK, Raina V: Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital. Indian J Nephrol 2009, 19(2):62-67.
• [40]Vladutiu DS, Cosa A, Neamtu A, State D, Braila M, Gherman M, Patiu IM, Dulau-Florea I: Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map? J Viral Hepat 2000, 7(4):313-319.
• [41]Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW: Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004, 65(6):2335-2342.
• [42]Hitzler WE, Runkel S: Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV. Transfusion 2001, 41(3):333-337.
• [43]Doghman NA MYA, Najem FI, SA E-S: Blood donor screening for hepatitis B and C in Benghazi: additional tests are needed. Libyan J Infect Dis 2007, 1(1):100-102.
• [44]Pereira BJ: Hepatitis C infection and post-transplantation liver disease. Nephrol Dial Transplant 1995, 10(Suppl 1):58-67.
• [45]Dusheiko G, Song E, Bowyer S, Whitcutt M, Maier G, Meyers A, Kew MC: Natural history of hepatitis B virus infection in renal transplant recipients–a fifteen-year follow-up. Hepatology 1983, 3(3):330-336.
• [46]Izopet J, Sandres-Saune K, Kamar N, Salama G, Dubois M, Pasquier C, Rostaing L: Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005, 77(1):70-76.
• [47]Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S: Hepatitis B and C in dialysis units in Iran: changing the epidemiology. Hemodial Int 2008, 12(3):378-382.
• [48]Karkar A, Abdelrahman M, Ghacha R, Malik TQ: Prevention of viral transmission in HD units: the value of isolation. Saudi J Kidney Dis Transpl 2006, 17(2):183-188.
• [49]Abu El Makarem MA, Abdel Hamid M, Abdel Aleem A, Ali A, Shatat M, Sayed D, Deaf A, Hamdy L, Tony EA: Prevalence of occult hepatitis B virus infection in hemodialysis patients from egypt with or without hepatitis C virus infection. Hepat Mon 2012, 12(4):253-258.